HUE056551T2 - Az akamprozát alkalmazása az ERK 1-2 aktiváció modulálására az FXS és az ASD állati modelljeiben, valamint az FXS és ASD diagnózissal rendelkezõ egyéneken - Google Patents
Az akamprozát alkalmazása az ERK 1-2 aktiváció modulálására az FXS és az ASD állati modelljeiben, valamint az FXS és ASD diagnózissal rendelkezõ egyénekenInfo
- Publication number
- HUE056551T2 HUE056551T2 HUE14854852A HUE14854852A HUE056551T2 HU E056551 T2 HUE056551 T2 HU E056551T2 HU E14854852 A HUE14854852 A HU E14854852A HU E14854852 A HUE14854852 A HU E14854852A HU E056551 T2 HUE056551 T2 HU E056551T2
- Authority
- HU
- Hungary
- Prior art keywords
- fxs
- asd
- acamprosate
- activation
- animal models
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/48—Nerve growth factor [NGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361890756P | 2013-10-14 | 2013-10-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE056551T2 true HUE056551T2 (hu) | 2022-02-28 |
Family
ID=52828619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE14854852A HUE056551T2 (hu) | 2013-10-14 | 2014-10-14 | Az akamprozát alkalmazása az ERK 1-2 aktiváció modulálására az FXS és az ASD állati modelljeiben, valamint az FXS és ASD diagnózissal rendelkezõ egyéneken |
Country Status (11)
Country | Link |
---|---|
US (2) | US10634677B2 (hu) |
EP (1) | EP3058371B1 (hu) |
JP (1) | JP6637414B2 (hu) |
AU (1) | AU2014337504B2 (hu) |
CA (1) | CA2926645C (hu) |
DK (1) | DK3058371T3 (hu) |
HU (1) | HUE056551T2 (hu) |
PL (1) | PL3058371T3 (hu) |
PT (1) | PT3058371T (hu) |
RU (1) | RU2696481C2 (hu) |
WO (1) | WO2015057736A1 (hu) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3058371T3 (pl) | 2013-10-14 | 2021-11-08 | Indiana University Research And Technology Corporation | Zastosowanie akamprozatu do modulowania aktywacji erk 1-2 w modelach zwierzęcych dla fxs i asd oraz u osób z rozpoznaniem fxs i asd |
WO2017147044A1 (en) * | 2016-02-22 | 2017-08-31 | Indiana University Research And Technology Corporation | Peptides and methods for treatment of neurodegenerative diseases |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6316635B1 (en) * | 1995-06-07 | 2001-11-13 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
EP0946179B1 (en) | 1996-03-11 | 2003-09-17 | Eli Lilly And Company | Use of olanzapine or a pharmaceutically acceptable salt for the manufacture of a medicament for the treatment of autism and mental retardation |
PL198599B1 (pl) | 1998-07-06 | 2008-07-31 | Nsgene As | Izolowany kwas nukleinowy neublastyny, wektor ekspresji, izolowana komórka, polipeptyd, sposób wytwarzania polipeptydu, oczyszczony polipeptyd, kompozycja, zastosowanie polipeptydu, sekwencja kwasu nukleinowego primera, sposób wytwarzania peptydów, sposób wytwarzania peptydu neublastyny, syntetyczny gen, peptyd neublastyny, przeciwciało, zastosowanie czynnika neurotroficznego neublastyny i zastosowanie kwasu nukleinowego |
US6593133B1 (en) | 1998-07-06 | 2003-07-15 | Nsgene A/S | Neurotrophic factors |
US6627625B1 (en) | 1999-08-16 | 2003-09-30 | Revaax Pharmaceuticals, Llc | Treatment of behavioral disorders with β-lactam compounds |
SE0300586L (sv) | 2003-03-04 | 2004-09-05 | Forskarpatent I Syd Ab | Diagnos av autism |
ES2897422T3 (es) | 2004-05-14 | 2022-03-01 | Vertex Pharma | Compuestos pirroles como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos |
US7595167B2 (en) | 2005-10-11 | 2009-09-29 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio |
WO2008060375A2 (en) | 2006-10-06 | 2008-05-22 | The Regents Of The University Of Californina | Upregulating bdnf levels to mitigate mental retardation |
CA2670116C (en) * | 2006-11-22 | 2015-03-10 | Seaside Therapeutics, Llc | Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism |
NZ577436A (en) | 2006-12-22 | 2012-05-25 | Genentech Inc | Death receptor 6 (dr6) antagonist inhibiting the binding of dr6 to amyloid precursor protein (app), and uses thereof in treating neurological disorders |
WO2008112772A2 (en) * | 2007-03-14 | 2008-09-18 | Baylor Research Institute | Gene expression in peripheral blood mononuclear cells from children with diabetes |
US20090082464A1 (en) * | 2007-09-07 | 2009-03-26 | Bernd Jandeleit | Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
US20090239888A1 (en) * | 2008-02-12 | 2009-09-24 | Wisconsin Alumni Research Foundation | Methods for Inhibiting Amyloid Precursor Protein and Beta-Amyloid Production and Accumulation |
KR101390607B1 (ko) * | 2008-07-14 | 2014-05-19 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 귀 질환 치료를 위한 제어 방출형 아폽토시스 조절 조성물 및 방법 |
PT2395990E (pt) | 2009-02-12 | 2015-02-09 | Univ Indiana Res & Tech Corp | Material e métodos de tratamento de transtornos do desenvolvimento incluindo autismo comórbido e idiopático |
US8008539B1 (en) | 2009-03-19 | 2011-08-30 | University Of South Florida | Generation of transgenic human soluble amyloid precursor protein alpha expressing mice |
US20130052644A1 (en) | 2010-04-30 | 2013-02-28 | Baltazar Gomez-Mancilla | Predictive Markers Useful in the Treatment of Fragile X Syndrome (FXS) |
WO2011150380A1 (en) | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
US9597312B2 (en) | 2010-08-19 | 2017-03-21 | Cognitive Research Enterprises, Inc. | Treatment of cognitive disorders associated with abnormal dendritic spines using PKC activators |
RU2465273C2 (ru) | 2010-08-31 | 2012-10-27 | Общество С Ограниченной Ответственностью "Биофарм-Меморейн" | ГЕТЕРОЦИКЛИЧЕСКИЕ НИЗКОМОЛЕКУЛЯРНЫЕ sAPP-МИМЕТИКИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
AU2013293167B2 (en) * | 2012-07-22 | 2019-04-18 | Indiana University Research And Technology Corporation | Modulation sAPP, sAPP alpha and BDNF levels in individuals diagnosed with FXS and ASD |
PL3058371T3 (pl) | 2013-10-14 | 2021-11-08 | Indiana University Research And Technology Corporation | Zastosowanie akamprozatu do modulowania aktywacji erk 1-2 w modelach zwierzęcych dla fxs i asd oraz u osób z rozpoznaniem fxs i asd |
-
2014
- 2014-10-14 PL PL14854852T patent/PL3058371T3/pl unknown
- 2014-10-14 CA CA2926645A patent/CA2926645C/en active Active
- 2014-10-14 EP EP14854852.2A patent/EP3058371B1/en active Active
- 2014-10-14 WO PCT/US2014/060527 patent/WO2015057736A1/en active Application Filing
- 2014-10-14 RU RU2016118551A patent/RU2696481C2/ru active
- 2014-10-14 PT PT148548522T patent/PT3058371T/pt unknown
- 2014-10-14 HU HUE14854852A patent/HUE056551T2/hu unknown
- 2014-10-14 JP JP2016522755A patent/JP6637414B2/ja active Active
- 2014-10-14 AU AU2014337504A patent/AU2014337504B2/en active Active
- 2014-10-14 US US15/029,596 patent/US10634677B2/en active Active
- 2014-10-14 DK DK14854852.2T patent/DK3058371T3/da active
-
2020
- 2020-03-13 US US16/818,854 patent/US11733243B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
RU2016118551A (ru) | 2017-11-21 |
US10634677B2 (en) | 2020-04-28 |
JP2016536293A (ja) | 2016-11-24 |
AU2014337504B2 (en) | 2020-01-30 |
EP3058371A4 (en) | 2017-04-19 |
CA2926645C (en) | 2022-10-25 |
RU2016118551A3 (hu) | 2018-07-24 |
JP6637414B2 (ja) | 2020-01-29 |
US20200225233A1 (en) | 2020-07-16 |
DK3058371T3 (da) | 2021-08-02 |
US20160266120A1 (en) | 2016-09-15 |
WO2015057736A1 (en) | 2015-04-23 |
PT3058371T (pt) | 2021-07-26 |
CA2926645A1 (en) | 2015-04-23 |
PL3058371T3 (pl) | 2021-11-08 |
US11733243B2 (en) | 2023-08-22 |
RU2696481C2 (ru) | 2019-08-02 |
EP3058371A1 (en) | 2016-08-24 |
EP3058371B1 (en) | 2021-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL239961A0 (en) | Useful real-time diagnostic results | |
HK1208296A1 (en) | Methods and apparatus to determine impressions using distributed demographic information | |
EP2827707A4 (en) | NON-HUMAN ANIMAL DEPRESSION MODELS AND METHODS OF USE THEREOF | |
EP2987106A4 (en) | ACQUIRING AND ANALYZING PHYSIOLOGICAL DATA | |
SG11201602236SA (en) | Animal models and therapeutic molecules | |
PL2941195T3 (pl) | Urządzenie do pomiaru analitów w skórze | |
IL264559A (en) | Methods and reagents for the evaluation of gestational diabetes | |
GB2525771B (en) | Methods and systems related to electrosurgical wands | |
EP2914987A4 (en) | DEVICE AND METHOD FOR VISUALIZING FORMING FEATURES | |
PL3004833T3 (pl) | Ulepszenia związane z pobieraniem próbek | |
GB2516343B (en) | Improvements in and relating to ophthalmoscopes | |
GB201322094D0 (en) | Methods and compositions relating to alzheimers disease | |
IL244590A0 (en) | Anti-epcam antibodies and methods of use | |
HK1222864A1 (zh) | 的小分子調節劑和其使用方法 | |
HK1222562A1 (zh) | 用於醫學診斷的組合物及方法 | |
EP2957925A4 (en) | STREAMING STOMOGRAPHIC PROCESS AND STREAMING TOMOGRAPHY DEVICE | |
HK1219636A1 (zh) | 經改善的皮膚及頭皮診斷裝置及方法 | |
EP3064161A4 (en) | Ultrasonic probe and ultrasonic treatment device | |
EP3060061A4 (en) | Use of probiotics in meat | |
EP2979645A4 (en) | ULTRASONIC DIAGNOSTIC DEVICE AND ULTRASONIC DIAGNOSTIC METHOD | |
EP2853591A4 (en) | HEMATOMIC HEMAZONE CELL LINE HLCZ01 AND USES THEREOF | |
PL3058371T3 (pl) | Zastosowanie akamprozatu do modulowania aktywacji erk 1-2 w modelach zwierzęcych dla fxs i asd oraz u osób z rozpoznaniem fxs i asd | |
EP3060163A4 (en) | Early determination of pregnancy status in ruminants | |
EP2971131A4 (en) | METHODS AND MATERIALS USING SIGNALING PROBES | |
EP2981556A4 (en) | HYALURONIC ACID BIOPOLYMERS ETHYLSULFONATED AND METHODS OF USE |